Article (Scientific journals)
Inhibiteurs des SGLT2 : nouvelle option pour prévenir ou traiter l’insuffisance cardiaque.
Scheen, André; Lancellotti, Patrizio
2021In Revue Médicale de Liège, 76 (4), p. 248-255
Peer reviewed
 

Files


Full Text
202104_06.pdf
Publisher postprint (756.7 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Benzhydryl Compounds; Diabetes Mellitus, Type 2/complications/drug therapy; Heart Failure/drug therapy; Humans; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use; Stroke Volume; Ventricular Function, Left; Gliflozin; Heart failure; Left ventricular ejection fraction; Renal insufficiency; Type 2 diabetes; Cardiovascular disease
Abstract :
[en] Gliflozins (sodium-glucose cotransporter type 2 inhibitors or SGLT2is) are the only glucose-lowering agents that have proven their ability to reduce major cardiovascular events, hospitalisations for heart failure and the progression to end-stage kidney disease in at risk patients with type 2 diabetes (T2D). One of the most marked and reproducible effects is the reduction in hospitalisations for heart failure. This protective effect was observed in all large prospective cardiovascular outcome trials, independently of the presence of heart failure at inclusion, and was confirmed in two dedicated trials that specifically targeted patients with heart failure and reduced left ventricular ejection fraction, with or without diabetes : DAPA-HF with dapagliflozin and EMPEROR-reduced with empagliflozin. The reduction in hospitalisations for heart failure appeared more marked when baseline renal function was impaired, including when estimated glomerular filtration rate (eGFR) was inferior to 45 ml/min/1.73 m². These favourable results contribute to give a privileged position to SGLT2is in more recent international guidelines produced by diabetologists, cardiologists and nephrologists. According to these guidelines, the prescription of SGLT2is should be extended to patients with an eGFR between 30 and 60 ml/min/1.73 m² as well to non-diabetic patients with heart failure and reduced ejection fraction. For other patients with preserved ejection fraction, one has to wait for further results from ongoing large prospective trials.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Lancellotti, Patrizio  ;  Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Language :
French
Title :
Inhibiteurs des SGLT2 : nouvelle option pour prévenir ou traiter l’insuffisance cardiaque.
Alternative titles :
[en] SGLT2 inhibitors, new option to prevent or treat heart failure
Publication date :
2021
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
76
Issue :
4
Pages :
248-255
Peer reviewed :
Peer reviewed
Available on ORBi :
since 02 September 2021

Statistics


Number of views
397 (6 by ULiège)
Number of downloads
726 (9 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
1

Bibliography


Similar publications



Contact ORBi